Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Core Insights - Medicus Pharma Ltd. is advancing clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next-generation GnRH antagonist [1] Financial and Operational Results - The company announced its financial and operating results for the quarter ending September 30, 2025 [1] - Important corporate updates were highlighted in the announcement [1]